12:00 AM
 | 
Aug 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Gevokizumab regulatory update

FDA granted Orphan Drug designation for Xoma's gevokizumab to treat non-infectious intermediate, posterior or pan-uveitis, or chronic non-infectious anterior uveitis. The compound, which is in Phase III...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >